ABOUT / 08
About TB-500 MD
An independent editorial dossier on the TB-500 literature — built to be scanned, checked, and trusted, with the full-length-versus-fragment caveat in plain view.
What this site is
TB-500 MD is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500, the Ac-LKKTETQ fragment of thymosin beta-4. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The "MD" in the name is editorial framing — a position this publisher occupies relative to the literature, a research dossier read with a measured, instrument-panel eye. It is not a claim that the site offers diagnosis, treatment, consultation, or prescription services, and it does not imply any medical staff or clinical capability. There is no doctor behind this board and nothing here is dispensed.
How we work
Every quantitative claim on this site maps to a numbered citation in the full reference list — a real study with a DOI and a PubMed link, or, for the regulatory facts, an FDA page. We built the site as a board of discrete tiles because the TB-500 evidence is, structurally, a set of separable findings rather than a single argument, and because separating them makes the most important editorial move visible: flagging where a result used full-length thymosin beta-4 (~4,963 Da) rather than the TB-500 heptapeptide (~889 Da), and where there is simply no human data for the fragment.
We do not recommend doses, we do not name vendors, and we describe what was administered to which species in which study rather than what anyone should take. Where the data are strong, we say so plainly; where they are thin or absent, we say that too. The goal is a dossier a reader can verify line by line, not a sales page.
What we do not do
We do not sell TB-500 or any other compound, and this site carries no storefront, price, or order pathway. We do not provide protocols, administration instructions, or clinical guidance. We do not assert future FDA decisions as fact. And we do not present unverified reclassification claims as settled — where the regulatory record is in motion, we describe the active review and label the pending matters as pending. This is general information about a research compound and its regulatory landscape, not medical or legal advice.